2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Limb-Girdle Muscular Dystrophy: new trials by email Literature Review of Limb-Girdle Muscular Dystrophy trials Research Report on Limb-Girdle Muscular Dystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of Transvenous Limb Perfusion in Human Muscular Dystrophy Retrograde high pressure transvenous perfusion with normal saline - Muscular Dystrophies, Duchenne Muscular Dystrophy | Phase 1 | Completed | University of North Carolina, Chapel Hill | 16 | 2009-03-01 | 2015-03-09 |
| Study Evaluating MYO-029 in Adult Muscular Dystrophy MYO-029 - Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy | Phase 1 / Phase 2 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 108 | 2005-02-01 | 2007-12-28 |
Muscular Dystrophies, Limb-Girdle (2) · Muscular Dystrophy, Duchenne (2) · Muscular Dystrophies (1) · Muscular Dystrophy, Facioscapulohumeral (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Muscular Diseases (2) · Muscular Disorders, Atrophic (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Neuromuscular Diseases (2) · Muscular Dystrophies (1)
Saline Solution (1) · Stamulumab (1)
University of North Carolina, Chapel Hill (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1)
United States (2)
U54AR056953 (1)